Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by T. Cai.
World Journal of Urology | 2016
Zafer Tandogdu; R. Bartoletti; T. Cai; Mete Cek; Magnus Grabe; Ekaterina Kulchavenya; Béla Köves; Vandana Menon; Kurt G. Naber; Tamara Perepanova; Peter Tenke; Björn Wullt; Truls E. Bjerklund Johansen; Florian Wagenlehner
AbstractObjectivenPrimary objective was to identify the (1) relationship of clinical severity of urosepsis with the pathogen spectrum and resistance and (2) appropriateness of using the pathogen spectrum and resistance rates of health-care-associated urinary tract infections (HAUTI) as representative of urosepsis. The secondary objective was to provide an overview of the pathogens and their resistance profile in patients with urosepsis.Population and MethodsnA point prevalence study carried out in 70 countries (2003–2013). Population studied included; 408 individuals with microbiologically proven urosepsis, 1606 individuals with microbiological proof of HAUTI and 27,542 individuals hospitalised in urology wards. Main outcomes are pathogens and resistance identified in HAUTIs and urosepsis including its clinical severity. A statistical model that included demographic factors (study year, geographical location, hospital setting) was used for analysis.ResultsAmongst urology practices, the prevalence of microbiologically proven HAUTI and urosepsis was 5.8 and 1.5xa0%, respectively. Frequent pathogens in urosepsis were E. coli (43xa0%), Enterococcus spp. (11xa0%), P. aeruginosa (10xa0%) and Klebsiella spp. (10xa0%). Resistance to commonly prescribed antibiotics was high and rates ranged from 8xa0% (imipenem) to 62xa0% (aminopenicillin/β lactamase inhibitors); 45xa0% of Enterobacteriaceae and 21xa0% of P. aeruginosa were multidrug-resistant. Resistance rates in urosepsis were higher than in other clinical diagnosis of HAUTI (Likelihood ratio <0.05).ConclusionsIt is not appropriate to use the pathogen spectrum and resistance rates of other HAUTIs as representative of urosepsis to decide on empirical treatment of urosepsis. Resistance rates in urosepsis are high, and precautions should be made to avoid further increase.
European urology focus | 2017
Gernot Bonkat; Olivier Braissant; T. Cai; Béla Köves; Truls E. Bjerklund Johansen; Robert Pickard; Rajan Veeratterapillay
Urine culture still has to be considered as the gold standard to rule out bacteriuria and should, therefore, be obtained prior to invasive endoscopic or open urological procedures to minimize the risk of severe infectious complications.
European Urology Supplements | 2015
T. Cai; Paolo Verze; Anna Brugnolli; Daniele Tiscione; Gianni Malossini; Lorenzo Giuseppe Luciani; C. Echher; F. Wagenlehner; Vincenzo Mirone; T.E. Bjerklund Johansen; Robert Pickard; R. Bartoletti
European Urology Supplements | 2018
Paolo Lanzafame; T. Cai; P. Caciagli; Alessandro Palmieri; Paolo Verze; Davide Arcaniolo; Vincenzo Mirone; Gianni Malossini
European Urology Supplements | 2018
Michele Rizzo; G. Campisciano; F. Migliozzi; Giovanni Liguori; Stefano Bucci; A. Cocci; T. Cai; Carlo Trombetta; M. Comar
European Urology Supplements | 2018
T. Cai; Daniele Tiscione; A. Cocci; Paolo Verze; Alessandro Palmieri; Vincenzo Mirone; Gianni Malossini
European Urology Supplements | 2018
T. Cai; Daniele Tiscione; Paolo Lanzafame; Lorenzo Giuseppe Luciani; R. Bartoletti; Gianni Malossini
European Urology Supplements | 2018
T. Cai; Sandra Mazzoli; Paolo Lanzafame; P. Caciagli; Daniele Tiscione; Gianni Malossini; Paolo Verze; Alessandro Palmieri; R. Bartoletti; Vincenzo Mirone
European Urology Supplements | 2018
Daniele Mattevi; G.L. Luciani; S. Chiodini; M. Puglisi; V. Vattovani; T. Cai; Gianni Malossini
European Urology Supplements | 2018
Lorenzo Giuseppe Luciani; Daniele Mattevi; S. Chiodini; M. Puglisi; V. Vattovani; T. Cai; Gianni Malossini